JP2011505414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011505414A5 JP2011505414A5 JP2010536523A JP2010536523A JP2011505414A5 JP 2011505414 A5 JP2011505414 A5 JP 2011505414A5 JP 2010536523 A JP2010536523 A JP 2010536523A JP 2010536523 A JP2010536523 A JP 2010536523A JP 2011505414 A5 JP2011505414 A5 JP 2011505414A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- composition
- subject
- item
- factor viii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 229940124135 Factor VIII inhibitor Drugs 0.000 claims description 6
- 108010054218 Factor VIII Proteins 0.000 claims description 4
- 102000001690 Factor VIII Human genes 0.000 claims description 4
- 108010051539 HLA-DR2 Antigen Proteins 0.000 claims description 4
- 208000009292 Hemophilia A Diseases 0.000 claims description 4
- 229960000301 factor viii Drugs 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 3
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 2
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 2
- 208000031220 Hemophilia Diseases 0.000 claims description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 2
- 102000043131 MHC class II family Human genes 0.000 claims description 2
- 108091054438 MHC class II family Proteins 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 208000013633 acquired hemophilia Diseases 0.000 claims description 2
- 230000030741 antigen processing and presentation Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 238000009256 replacement therapy Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 description 7
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0723712.6 | 2007-12-04 | ||
| GBGB0723712.6A GB0723712D0 (en) | 2007-12-04 | 2007-12-04 | Peptides |
| PCT/GB2008/003996 WO2009071886A1 (en) | 2007-12-04 | 2008-12-03 | Fviii peptides and their use in tolerising haemophiliacs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014023217A Division JP6063402B2 (ja) | 2007-12-04 | 2014-02-10 | Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011505414A JP2011505414A (ja) | 2011-02-24 |
| JP2011505414A5 true JP2011505414A5 (enExample) | 2012-10-25 |
| JP5501245B2 JP5501245B2 (ja) | 2014-05-21 |
Family
ID=38982965
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010536523A Active JP5501245B2 (ja) | 2007-12-04 | 2008-12-03 | Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用 |
| JP2014023217A Expired - Fee Related JP6063402B2 (ja) | 2007-12-04 | 2014-02-10 | Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014023217A Expired - Fee Related JP6063402B2 (ja) | 2007-12-04 | 2014-02-10 | Ｆｖｉｉｉペプチドおよび血友病を寛容化することにおけるその使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8445448B2 (enExample) |
| EP (1) | EP2227488B3 (enExample) |
| JP (2) | JP5501245B2 (enExample) |
| KR (1) | KR101519840B1 (enExample) |
| CN (2) | CN103709234B (enExample) |
| AU (1) | AU2008332968B2 (enExample) |
| BR (1) | BRPI0820143A2 (enExample) |
| CA (2) | CA3005013C (enExample) |
| CY (1) | CY1115168T1 (enExample) |
| DK (1) | DK2227488T6 (enExample) |
| EA (1) | EA019370B1 (enExample) |
| EC (1) | ECSP10010327A (enExample) |
| ES (1) | ES2458315T7 (enExample) |
| GB (1) | GB0723712D0 (enExample) |
| HR (1) | HRP20140344T4 (enExample) |
| IL (1) | IL205780A (enExample) |
| MX (1) | MX2010006084A (enExample) |
| MY (1) | MY150995A (enExample) |
| NZ (1) | NZ585217A (enExample) |
| PL (1) | PL2227488T6 (enExample) |
| PT (1) | PT2227488E (enExample) |
| SI (1) | SI2227488T1 (enExample) |
| UA (1) | UA101003C2 (enExample) |
| WO (1) | WO2009071886A1 (enExample) |
| ZA (1) | ZA201002997B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1311542T1 (sl) | 2000-08-21 | 2009-02-28 | Apitope Technology Bristol Ltd | Tolerogenski peptidi |
| GB0801513D0 (en) * | 2008-01-28 | 2008-03-05 | Circassia Ltd | Peptides from factor VIII |
| SI2300497T1 (sl) * | 2008-06-24 | 2013-02-28 | Octapharma Ag | Postopek za äťiĺˇäťenje koagulacijskega faktorja viii |
| GB0908515D0 (en) * | 2009-05-18 | 2009-06-24 | Apitope Technology Bristol Ltd | Peptide |
| US20120135917A1 (en) * | 2009-06-16 | 2012-05-31 | Eisaku Yoshihara | Anti-Gram Negative Bacteria Agent |
| DK2632479T3 (en) * | 2010-10-27 | 2017-08-07 | Baxalta GmbH | FVIII PEPTIDES FOR IMMUNT TOLERANCE INDUCTION AND IMMUNODIAGNOSTICS |
| PL3453402T3 (pl) | 2012-01-12 | 2022-03-21 | Bioverativ Therapeutics Inc. | Zmniejszenie immunogenności przeciwko czynnikowi viii u osób poddawanych terapii czynnikiem viii |
| PL2917232T3 (pl) * | 2012-11-12 | 2017-09-29 | Apitope International Nv | Pochodzące od czynnika VIII peptydy do zastosowania w leczeniu hemofilii A |
| GB201314052D0 (en) | 2013-08-06 | 2013-09-18 | Apitope Int Nv | Peptides |
| WO2017096329A1 (en) | 2015-12-03 | 2017-06-08 | Juno Therapeutics, Inc. | Modified chimeric receptors and related compositions and methods |
| BR112019011198A2 (pt) | 2016-12-02 | 2019-12-17 | Bioverativ Therapeutics Inc | métodos de indução de tolerância imune a fatores de coagulação |
| US12077607B2 (en) * | 2021-09-23 | 2024-09-03 | University Of Utah Research Foundation | Functional and therapeutic effects of PAR4 cleavage by cathepsin G |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT94427A (pt) | 1989-06-20 | 1991-03-20 | Scripps Clinic Res | Processo para a preparacao de polipeptidos que inibem a ligacao de factor viii humano a fosfolipidos |
| BR9806793A (pt) * | 1997-01-22 | 2000-05-16 | Univ Texas | Processos e composições de fator tissular para coagulação e tratamento de tumores. |
| SI1311542T1 (sl) * | 2000-08-21 | 2009-02-28 | Apitope Technology Bristol Ltd | Tolerogenski peptidi |
| US20040096456A1 (en) * | 2000-12-01 | 2004-05-20 | Conti-Fine Bianca M | Method to treat hemophilia |
| AU2002233340B2 (en) * | 2001-02-19 | 2008-05-22 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| AU2002312660A1 (en) * | 2001-05-31 | 2002-12-16 | D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
| JP2005538694A (ja) * | 2002-04-18 | 2005-12-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 修飾されたｖｉｉｉ因子 |
| SI1729795T1 (sl) * | 2004-02-09 | 2016-04-29 | Human Genome Sciences, Inc. | Albuminski fuzijski proteini |
| WO2006003183A1 (de) | 2004-07-02 | 2006-01-12 | Alois Jungbauer | Peptide zur blockierung von fviii-inhibitoren |
| IL229645A0 (en) * | 2013-11-26 | 2014-03-31 | Omrix Biopharmaceuticals Ltd | A dry bandage containing thrombin and pectin |
-
2007
- 2007-12-04 GB GBGB0723712.6A patent/GB0723712D0/en not_active Ceased
-
2008
- 2008-03-12 UA UAA201008194A patent/UA101003C2/uk unknown
- 2008-12-03 SI SI200831186T patent/SI2227488T1/sl unknown
- 2008-12-03 CN CN201310392152.6A patent/CN103709234B/zh not_active Expired - Fee Related
- 2008-12-03 NZ NZ585217A patent/NZ585217A/xx not_active IP Right Cessation
- 2008-12-03 EA EA201070681A patent/EA019370B1/ru not_active IP Right Cessation
- 2008-12-03 KR KR1020107011743A patent/KR101519840B1/ko not_active Expired - Fee Related
- 2008-12-03 US US12/746,141 patent/US8445448B2/en not_active Expired - Fee Related
- 2008-12-03 HR HRP20140344TT patent/HRP20140344T4/hr unknown
- 2008-12-03 AU AU2008332968A patent/AU2008332968B2/en not_active Ceased
- 2008-12-03 PT PT88557723T patent/PT2227488E/pt unknown
- 2008-12-03 ES ES08855772.3T patent/ES2458315T7/es active Active
- 2008-12-03 PL PL08855772T patent/PL2227488T6/pl unknown
- 2008-12-03 CN CN200880119313.1A patent/CN101889024B/zh not_active Expired - Fee Related
- 2008-12-03 CA CA3005013A patent/CA3005013C/en active Active
- 2008-12-03 DK DK08855772.3T patent/DK2227488T6/en active
- 2008-12-03 WO PCT/GB2008/003996 patent/WO2009071886A1/en not_active Ceased
- 2008-12-03 EP EP08855772.3A patent/EP2227488B3/en active Active
- 2008-12-03 JP JP2010536523A patent/JP5501245B2/ja active Active
- 2008-12-03 MY MYPI20102567 patent/MY150995A/en unknown
- 2008-12-03 CA CA2707559A patent/CA2707559C/en active Active
- 2008-12-03 MX MX2010006084A patent/MX2010006084A/es active IP Right Grant
- 2008-12-03 BR BRPI0820143 patent/BRPI0820143A2/pt not_active Application Discontinuation
-
2010
- 2010-04-29 ZA ZA2010/02997A patent/ZA201002997B/en unknown
- 2010-05-13 IL IL205780A patent/IL205780A/en active IP Right Grant
- 2010-07-02 EC EC2010010327A patent/ECSP10010327A/es unknown
-
2014
- 2014-02-10 JP JP2014023217A patent/JP6063402B2/ja not_active Expired - Fee Related
- 2014-04-15 CY CY20141100281T patent/CY1115168T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011505414A5 (enExample) | ||
| Lhuillier et al. | Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control | |
| Paunovska et al. | Using large datasets to understand nanotechnology | |
| JP2012515778A5 (enExample) | ||
| US20170312334A1 (en) | Methods and compositions for treating inflammatory disorders | |
| PH12017502286A1 (en) | Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi) | |
| CL2018000537A1 (es) | Anticuerpo anti-factor d del complemento; polinucleótido codificante; vector que comprende dicho polinucleótido; célula húesped que comprende dicho vector; método de fabricación de anticuerpo; composición farmacéutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares (divisional de cl 1001-2009). | |
| TW201706297A (zh) | 用於抗肺癌，包括ｎｓｃｌｃ及其他癌症的免疫治療的新穎胜肽及胜肽的組合 | |
| Zhang et al. | Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients | |
| Stone et al. | Genomics of human fibrotic diseases: disordered wound healing response | |
| MX2011012311A (es) | Marcadores geneticos asociados con la respuesta al interferon alfa. | |
| Mirizio et al. | Genetic signatures from RNA sequencing of pediatric localized scleroderma skin | |
| MX2010002716A (es) | Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago. | |
| RU2013126581A (ru) | Мутанты стрептокиназы и их ковалентно модифицированные формы | |
| JP2015522264A5 (enExample) | ||
| JP2019500057A (ja) | ネオエピトープのウイルス送達のための改善された組成物および方法ならびにその使用 | |
| Tessier et al. | Exploration of nuclear body-enhanced sumoylation reveals that PML represses 2-cell features of embryonic stem cells | |
| JP2012527440A5 (enExample) | ||
| FI20011664A7 (fi) | Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö | |
| Paul et al. | Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy | |
| WO2018200489A1 (en) | Il-8, il-6, il-1b and tet2 and dnmt3a in atherosclerosis | |
| Kjer-Hansen et al. | Protein isoform-centric therapeutics: expanding targets and increasing specificity | |
| Turcot et al. | Comparison of the dipeptidyl peptidase-4 gene methylation levels between severely obese subjects with and without the metabolic syndrome | |
| MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
| JP2010526090A5 (enExample) |